As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Continued Unmet Needs and Track New Launches
Spherix Global Insights releases market landscape evolution study paired with new research tracking familiarity and uptake of Novartis’ Fabhalta and Alexion/AstraZeneca’s Voydeya. EXTON, PA., June 26, 2024 – Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder in which red blood cells prematurely break apart, a process known as hemolysis. While the symptoms can vary […]
Spherix Global Insights Expands Therapeutic Area Coverage into Hematology
Spherix diversifies portfolio with strategic entry into classical hematology, tapping into a specialty with a high unmet patient need and expansive market growth. EXTON, PA., June 10, 2024 — Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, is excited to announce its strategic […]
